Analyst upgrades:

• Jefferies upgraded Starbucks (SBUX) to buy from hold, citing EPS and revenue momentum heading into 2010. The firm raised its target to $25 from $22.
• Soleil upgraded Zions Bancorp (ZION) to buy from hold on valuation as it believes the recent pullback provides an attractive entry point. The firm has a $17.50 price target on shares.
• RBC Capital expects Rigel Pharmaceuticals (RIGL) to sign a partnership for R788 in the next four months to run its global Phase III program. Shares were upgraded to outperform from sector perform and its target was raised to $11 from $9.
• Deere (DE) was upgraded to overweight from equal weight at Morgan Stanley.
• Shire (SHPGY) was raised to outperform from market perform at Bernstein.
• Ann Taylor (ANN) was upgraded to overweight from market weight at Thomas Weisel.
• J.M. Smucker (SJM) was upgraded to overweight from neutral at JPMorgan.

Analyst upgrades:

• Barclays believes Disney (NYSE: DIS) is the best positioned company for "media's digital evolution." The firm upgraded shares to Overweight from Underweight and has a $32 target on shares.
  
• Oppenheimer upgraded Semtech (NASDAQ: SMTC) to Outperform from Perform after channel checks indicated improved inventory levels, better product mix, and market share gains. The firm set a $20 target on the stock.
  
• RBC Capital expects Rigel's (NASDAQ: RIGL) R788 in RA to achieve its primary endpoint in the Phase II trials. Shares were upgraded to Sector Perform from Underperform and the price target was raised to $8 from $6.
• WebMD (NASDAQ: WBMD) was upgraded to Accumulate from Sell at ThinkEquity.
  
• International Game Tech (NYSE: IGT) was raised to Conviction Buy from Neutral at Goldman.
  
• Infineon (NYSE: IFX) was lifted at Banc of America/Merrill to Buy from Neutral.

Analyst upgrades:

• Merrill upgraded Kraft Foods (NYSE: KFT) to Buy from Neutral citing progress in the company's turnaround plan, execution, and 2009 earnings growth.
  
• Thomas Weisel raised Express Scripts (NASDAQ: ESRX) to Overweight from Market Weight and believes the company's core business remains strong and that valuation is attractive.
  
• Friedman Billings upgraded shares of Symantec (NASDAQ: SYMC) to Outperform from Market Perform on valuation after checks indicated the company should meet Q2 expectations.
• NeuStar (NSR) was upgraded to Outperform from Neutral at Baird.
  
• UBS raised Advance Auto Parts (NYSE: AAP) to Neutral from Sell.
  
• Goldman upgraded Royal Dutch Shell (NYSE: RDS.A) to Buy from Neutral.

Analyst downgrades:

• Friedman Billings downgraded shares of Zions Bancorp (NASDAQ: ZION) to Market Perform from Outperform and lowered its target to $33 from $43 following the company's Q3 results, as they believe near-term credit trends and concerns surrounding its securities portfolio will limit upside. Shares were also downgraded at JP Morgan to Neutral from Overweight due to deteriorating credit trends.
  
• Banc of America cut Monster (NASDAQ: MNST) to Neutral from Buy to reflect a lack of margin stability and their belief consensus estimates remain too high.
  
• Barclays downgraded Avis Budget Group (NYSE: CAR) to Equal Weight from Overweight citing the global economic slowdown and refinancing risk.
• Johnson Controls (NYSE: JCI), Luxottica (NYSE: LUX) and ArvinMeritor (NYSE: ARM) were cut to Neutral from Buy at Goldman.
  
• Luxottica was also downgraded at HSBC to Neutral from Overweight.
  
• JP Morgan cut AuthenTec (NASDAQ: AUTH) to Underweight from Neutral.

Analyst initiations:

• Janney Montgomery believes Gladstone Capital's (NASDAQ: GLAD) management team and lower portfolio investment risk profile warrant a premium valuation. The firm started shares with a Buy rating and $13 target.
• CommVault (NASDAQ: CVLT) was initiated with a Buy rating and $14 target at Cantor, as the firm finds the stock attractively valued given its secular growth rate potential.
  
• KeyBanc is positive on Papa John's (NASDAQ: PZZA) management team, growth potential, cost initiatives, and differentiation. Shares were assumed with a Buy rating and $30 target.
• Arris (NASDAQ: ARRS) was initiated at Jefferies with a Hold rating and $7 target.
  
• Rigel Pharmaceuticals (NASDAQ: RIGL) was initiated at Banc of America with a Neutral rating and $21 target.
  
• Morgan Stanley started Hansen Natural (NASDAQ: HANS) with an Equal Weight rating.

Analyst upgrades:

• Barclays upgraded the Integrated Oil sector to Positive from Neutral citing valuations. Note that Exxon Mobil (NYSE: XOM) was upgraded to Overweight from Equal Weight based on valuation.
  
• After Force Protection (NASDAQ: FRPT) reported that its 1H08 sales increased more than 200%, Stanford thinks that Force Protection could be poised for several new opportunities in 2009 and they believe the company's risk is already priced into the stock; the firm raised Force Protection to Hold from Sell.
  
• Cowen expects eHealth (NASDAQ: EHTH) to benefit from the steady decline in employer-sponsored health insurance offered by small businesses and reduced regulatory risk, among other reasons. The firm upgraded shares to Outperform from Neutral.
• Allied Capital (NYSE: ALD) was upgraded to Market Perform from Underperform at BMO Capital.
  
• Caris upgraded Carmike Cinemas (NASDAQ: CKEC) to Above Average from Average.
  
• International Flavors & Fragrances (NYSE: IFF) was upgraded to Neutral from Underweight at JP Morgan.

Analyst upgrades:

• Goldman upgraded shares of British Sky Broadcasting (NYSE: BSY) to Buy from Neutral and added the company to the Conviction Buy List as they find the stock oversold at current levels.
  
• Goldman also added Publicis (OTC: PUBGY) to the Conviction Buy List and upgraded shares to Buy from Neutral as they find the stock cheap at current levels.
• Oneok (NYSE: OKE) was upgraded to Overweight from Equal Weight at Lehman.
  
• UBS raised Wimm-Bill-Dann Foods (NYSE: WBD) to Buy from Neutral.

Analyst downgrades:

• Baird downgraded Amylin Pharma (NASDAQ: AMLN) to Neutral from Outperform and said they are incrementally more cautious on the commercial performance of Amylin's Byetta following the yesterday's update. Amylin's target was lowered to $27 from $37. Soleil recommends investors avoid Amylin with the disclosure last night of four additional cases of mortality associated with pancreatitis in patients who were on Byetta. The firm cut shares to Sell from Hold and lowered their target to $20 from $25.
  
• Citigroup downgraded shares of AMR Corp. (NYSE: AMR) to Sell from Hold on valuation as they find the stock expensive following the recent run-up. The firm raised their target to $9 from $6.70 to reflect the drop in crude prices.
  
• J Crew (NYSE: JCG) was downgraded to Hold from Buy at Brean Murray following the weak Q2 report and guidance.
• JMP Securities downgraded Quality Systems (NASDAQ: QSII) to Market Perform from Outperform.
  
• National Grid (NYSE: NGG) was lowered to Equal Weight from Overweight at Lehman.

Analyst initiations:

MOST NOTEWORTHY: The Metals and Mining sector, Lamar Advertising and Rigel Pharmaceuticals were today's noteworthy initiations:

• Banc of America initiated the Metals and Mining sector with an Equal Weight rating and believes investors should take a selective approach to stocks in the group. The firm initiated Alcoa (NYSE: AA) and RTI International Metals (NYSE: RTI) with Buy ratings and a $44 target and $41 target, and started Allegheny Tech (NYSE: ATI), Century Aluminum (NASDAQ: CENX) and Titanium Metals (NYSE: TIE) with Neutral ratings and a $64 target, $58 target and $12 target, respectively.
  
• Lamar Advertising (NASDAQ: LAMR) was initiated at Caris with an Above Average rating and $40 target. Caris is positive on the company's North American focus and exposure to the aggressive deployment of digital boards.
  
• Stanford believes Rigel Pharma's (NASDAQ: RIGL) lead drug R788 has the potential to be the first oral drug for rheumatoid arthritis and expects clinical news flow and partnerships to serve as catalysts. Shares were initiated with a Buy rating and $30 target.

OTHER INITIATIONS:

• Thomas Weisel assumed Salesforce.com (NYSE: CRM) with an Overweight rating and $90 target.
  
• International Flavors (NYSE: IFF) was initiated at Lehman with an Underweight rating.
  
• JP Morgan started Ares Capital (NASDAQ: ARCC) with an Underweight rating.

Armored vehicle maker Force Protection (NASDAQ: FRPT) has been slammed down to the single digits on fears that its sole product might be on the way out because of cuts in government spending. Who knows? The CEO says the company is doing fine, but the downtrending stock price is much more convincing. If the stock price is meant to make up lost ground, it should have no problem breaking out past $6, which it has not been able to do for the past few months. I'd avoid until the stock shows some strength.

Within the past few days, IDM Pharmacueticals (NASDAQ: IDMI) has had a huge run-up from under $1 to nearly $4 and a substantial drop to just under $2 -- all due to some positive drug news that was already known since November 2007, and of course the CEO's optimism about European approval. Do I believe the CEO? Yeah right! My distrust of CEOs is dwarfed only by my distrust of biotech CEOs! This company is not in the same league as other recently hot biotechs like Savient Pharmaceuticals (NASDAQ: SVNT) and Rigel Pharmaceuticals (NASDAQ: RIGL). Avoid, with a short bias on any spikes.

When I wrote this article about A-Power Generation Systems (NASDAQ: APWR), all the variables were aligned for a great run-up. I wanted to hold, but the volume and share price didn't live up to my expectations, so I sold quickly. Now, this company, potentially the new First Solar (NASDAQ: FSLR) of wind energy, has nearly retraced to its original breakout area around $15, so the risk has gone down ... but so has the reward. If you're a long-term investor, this is a solid choice, but I need it to break its previous highs at $19 to make me a buyer again. Avoid, with a long bias if it breaks out.

MOST NOTEWORTHY: U.S. refiners, Rigel Pharma and JetBlue were today's noteworthy upgrades:

• Goldman upgraded the U.S. Refiners to Attractive from Neutral, citing valuations; the firm raised its rating on CVR Energy (NYSE:CVI) and Holly Corp (NYSE:HOC) to Buy from Neutral.
  
• Lehman upgraded shares of Rigel Pharma (NASDAQ:RIGL) to Overweight from Equal Weight following the company's positive R788 data.
  
• Bear Stearns said the Lufthansa (DLAKY) investment gives JetBlue (NASDAQ:JBLU) some breathing room to execute on its turnaround but notes the company's long-term strategy remains in question. Bear raised its rating on JetBlue to Peer Perform from Underperform.

OTHER UPGRADES:

• UBS upgraded Disney (NYSE:DIS) to Buy from Neutral.
  
• Wachovia upgraded Jack in the Box (NYSE:JBX) to Outperform from Market Perform.
  
• Jefferies upgraded United Online (NASDAQ:UNTD) to Buy from Hold.

MOST NOTEWORTHY: Global pharmaceutical stocks, Rigel Pharmaceuticals and Brightpoint were today's noteworthy initiations:

• Bernstein initiated global pharmaceutical stocks with a Cautious view. The firm initiated Merck & Co Inc (NYSE: MRK), Schering Plough Corporation (NYSE: SGP) and Wyeth (NYSE: WYE) with Outperform ratings, as well as Bristol-Myers Squibb Company (NYSE: BMY) and Eli Lilly & Company (NYSE: LLY) with Market Perform ratings.
  
• CIBC resumed coverage of Rigel Pharmaceuticals Inc (NASDAQ: RIGL) with a Sector Outperformer rating and $16 target. The firm expects near-term upside to be driven by positive phase 2 results of R788 in rheumatoid arthritis, expected in December, and thinks the company's strong scientific platform will support long-term appreciation.
  
• Bear Stearns started Brightpoint Incorporated (NASDAQ: CELL) with an Outperform rating and $20 target, as they are positive on Brightpoint's merger with Dangaard given the significant synergies and diversification it provides.

OTHER INITIATIONS:

• Genitope Corporation (NASDAQ: GTOP) was initiated with a Neutral rating at Merriman.
  
• Grubb & Ellis Company (NYSE: GBE) was reinstated with an Outperform rating at William Blair.
  
• Roth Capital started Emcore Corporation (NASDAQ: EMKR) with a Buy rating and $13.80 target.
  
• Morgan Stanley started ING Groep NV (NYSE: ING) with an Equal Weight rating.

MOST NOTEWORTHY: Alcoa (AA), Rigel Pharma (RIGL), Isis Pharma (ISIS), Cytokinetics (CYTK) and F5 Networks (FFIV) were today's noteworthy initiations:

• RBC believes shares are expensive, but feels Alcoa (NYSE: AA) has put itself in play and a bid for the company is possible. The firm resumed coverage with a Sector Perform rating and a $51 target.

• Credit Suisse initiated Rigel Pharmaceuticals (NASDAQ: RIGL) with an Outperform rating, believing R788 in ITP alone justifies current value, while RA and pipeline provide potential upside.

• Isis Pharmaceuticals (NASDAQ: ISIS) was initiated with a Buy rating and $17 target at Jefferies; the firm believes Isis's pipeline holds promise and appears under appreciated at the current valuation.

• Credit Suisse is positive on Cytokinetics (NASDAQ: CYTK) congestive heart failure candidate CK-453 and views the market as undeserved, starting shares with an Outperform rating and $15 target.

• Unterberg initiated shares of F5 Networks (NASDAQ: FFIV) with a Market Perform based on valuation...

OTHER INITIATIONS:

• Credit Suisse initiated Mobile Mini (NASDAQ: MINI) with a Neutral rating.

• Art Technology (NASDAQ: ARTG) was initiated with a Buy rating at Pacific Growth.

• Banc of America started Grant Prideco (NYSE: GRP) share with a Buy rating and $67 target.

• Morgan Joseph initiated Harris Stratex Networks (NASDAQ: HSTX) with a Buy rating.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).